Press releases

Publication shows significant benefits of using intraoperative Glycosorb[®] treatment for blood group incompatible pediatric heart transplants

Tue, Jun 15 2021, 13:00 GMT+0200 | Press release

Data were collected for all blood group incompatible heart transplants performed between January 1, 2000, and June 1, 2020, a total of 37 transplants. Of these, plasma exchange (PE) was used for 27 transplants and 10 were performed with intraoperative Glycosorb® treatment.

For practical reasons, PE was usually carried out only in smaller children due to the large volumes of blood products required for such treatment. When a recipient is exposed to multiple, for the recipient foreign donor sources (of other tissue), the risk of transfusion related complications increases, as well as the risk of haemodynamic instability. Glycosorb® ABO was primarily introduced to address these problems.

The study shows, among other things, that the Glycosorb®-treated patients were significantly older and that the amount of blood products used during hospitalization was significantly lower compared to the PE patients. The average age of the 27 children in the PE group was 0.7 years and 4.1 years for the 10 children in the Glycosorb® group.

In the article(1), the authors conclude that the use of Glycosorb® ABO means that blood group incompatible heart transplants can be performed even in older and larger children, thereby providing an opportunity to increase the number of recipients. Another conclusion is the significantly reduced use of blood products when using Glycosorb® ABO compared to PE. Glycosorb® ABO was introduced at GOSH in 2015 and until now GOSH has published three articles on the subject. 

"As one of the world's largest clinics for pediatric heart transplants, we are very happy and proud that GOSH uses Glycosorb® ABO as standard treatment for blood group incompatible heart transplants. Treatment with Glycosorb® ABO means that more children are given the opportunity to undergo transplantation in a safer way. These are key factors for further expansion in this segment." says Pontus Nobréus, CEO of Glycorex Transplantation AB.

Every year, more than 8,000 heart transplants are performed globally, of which up to 700 are pediatric transplants. Heart transplants are currently performed routinely in many pediatric centers and over 100 centers worldwide are reported in the International Thoracic Transplant Registry.

"This publication demonstrates the clinical breadth of our technology in the transplantation area and the potential that exists for Glycosorb® ABO even outside the kidney area." concludes Pontus Nobréus.
 

(1) Richard Issitt, John Booth, Richard Crook, Alex Robertson, Victoria Molyneux, Rebecca Richardson, Nigel Cross, Michael Shaw, Victor Tsang, Vivek Muthurangu, Neil J Sebire, Michael Burch, Matthew Fenton
Intraoperative anti-A/B immunoadsorption is associated with significantly reduced blood product utilisation with similar outcomes in paediatric ABO-incompatible heart transplantation                

The Journal of Heart and Lung Transplantation 2021, ISSN 1053-2498

https://doi.org/10.1016/j.healun.2021.05.010.

https://www.sciencedirect.com/science/article/pii/S1053249821023251

News in swedish

Publication shows significant benefits of using intraoperative Glycosorb[®] treatment for blood group incompatible pediatric heart transplants

Tue, Jun 15 2021, 13:00 GMT+0200 | Press release

Data were collected for all blood group incompatible heart transplants performed between January 1, 2000, and June 1, 2020, a total of 37 transplants. Of these, plasma exchange (PE) was used for 27 transplants and 10 were performed with intraoperative Glycosorb® treatment.

For practical reasons, PE was usually carried out only in smaller children due to the large volumes of blood products required for such treatment. When a recipient is exposed to multiple, for the recipient foreign donor sources (of other tissue), the risk of transfusion related complications increases, as well as the risk of haemodynamic instability. Glycosorb® ABO was primarily introduced to address these problems.

The study shows, among other things, that the Glycosorb®-treated patients were significantly older and that the amount of blood products used during hospitalization was significantly lower compared to the PE patients. The average age of the 27 children in the PE group was 0.7 years and 4.1 years for the 10 children in the Glycosorb® group.

In the article(1), the authors conclude that the use of Glycosorb® ABO means that blood group incompatible heart transplants can be performed even in older and larger children, thereby providing an opportunity to increase the number of recipients. Another conclusion is the significantly reduced use of blood products when using Glycosorb® ABO compared to PE. Glycosorb® ABO was introduced at GOSH in 2015 and until now GOSH has published three articles on the subject. 

"As one of the world's largest clinics for pediatric heart transplants, we are very happy and proud that GOSH uses Glycosorb® ABO as standard treatment for blood group incompatible heart transplants. Treatment with Glycosorb® ABO means that more children are given the opportunity to undergo transplantation in a safer way. These are key factors for further expansion in this segment." says Pontus Nobréus, CEO of Glycorex Transplantation AB.

Every year, more than 8,000 heart transplants are performed globally, of which up to 700 are pediatric transplants. Heart transplants are currently performed routinely in many pediatric centers and over 100 centers worldwide are reported in the International Thoracic Transplant Registry.

"This publication demonstrates the clinical breadth of our technology in the transplantation area and the potential that exists for Glycosorb® ABO even outside the kidney area." concludes Pontus Nobréus.
 

(1) Richard Issitt, John Booth, Richard Crook, Alex Robertson, Victoria Molyneux, Rebecca Richardson, Nigel Cross, Michael Shaw, Victor Tsang, Vivek Muthurangu, Neil J Sebire, Michael Burch, Matthew Fenton
Intraoperative anti-A/B immunoadsorption is associated with significantly reduced blood product utilisation with similar outcomes in paediatric ABO-incompatible heart transplantation                

The Journal of Heart and Lung Transplantation 2021, ISSN 1053-2498

https://doi.org/10.1016/j.healun.2021.05.010.

https://www.sciencedirect.com/science/article/pii/S1053249821023251

Subscribe to our releases

Choose categories

Contact information

The subscription service is provided by Cision.se and your information will be stored on their servers. The information will only be used to send you notifications when new releases are published. No personal information will be shared with any outside parties. Read more about our Privacy Policy.

News

Pontus Nobréus, CEO presenting Glycorex Transplantation on Redeye Growth Day june 2.
Presentationen >>

Download the presentationen >>

 

 

Pontus Nobréus, CEO presenting Glycorex Transplantation  BioStock Life Science Spring Summit on May 26
https://youtu.be/5fpTsNENiO8

Download the presentation >>

Glycorex Transplantation is a proud collaborator with The Hospital Clínic de Barcelona in Spain. It recently became the first hospital in Spain to carry out more than 1,000 living donor kidney transplants. To celebrate this milestone, a campaign called “A thousand transplants, a thousand stories” was launched to increase public awareness and encourage living donor kidney donations. https://www.clinicbarcelona.org/en/news/the-hospital-clinic-the-first-hospital-in-spain-to-carry-out-1-000-living-donor-kidney-transplants

REDEYE GROWTH DAY
Pontus Nobréus, CEO of Glycorex Transplantation will present at the Redeye Growth Day on June 2, 2021 at 08:50 CET.
Link to live streaming: https://www.redeye.se/events/808637/redeye-growth-day-2021

Glycorex Transplantation participates in the BioStock Life Science Spring Summit 2021. CEO Pontus Nobréus will present the company at the BioStock Life Science Spring Summit on May 26-27. For more information please visit: www.summit.biostock.se

Tomorrow, april 29th, Dr Guirado from Spain will discuss ABO incompatible kidney transplantations in a live Zoom seminar, arranged by our distributor in Mexcio, Ryse Médica and Sociedad Mexicana De Transplantes.

https://us02web.zoom.us/j/85789158554

Scheelevägen 27 | SE-223 63 Lund, Sweden

Phone: +46 46 286 52 30  | Fax: +46 46-286 52 39
E-mail: info@glycorex.com

Org.nr: 556519-7372

© 2021 Glycorex Transplantation AB. Registered office in Lund, Sweden . All rights reserved.